Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon Alpha-2b in Metastatic or Unresectable Clear Cell Renal Cell Carcinoma
NCT00293527Phase 2Withdrawn
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Modality
- Cytokines & Interferons
01
Overview
A Phase 2 trial of interferon alfa-2b in clear cell renal cell carcinoma (ccRCC), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Status: withdrawn.
02
Drugs
interferon alfa-2b
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT00293527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00293527.